PARP inhibitor selectively triggers anti-tumor immunity in ERCC1- or BRCA-defective contexts, indicating that PARP inhibitors might promote therapeutic effects by inhibiting DNA damage repair and activating anti-tumor effect in populations with DNA repair defect (Figure 2) (48, 49). This evidence concerns the gene ERCC1 and neoplasm.